Chinese Firm Launches Phase-3 COVID-19 Vaccine Trial in UAE

Chinese Firm Launches Phase-3 COVID-19 Vaccine Trial in UAE

Published24 Jun 2020, 06:05 AM IST
1 min read

China's inactivated COVID-19 vaccine candidate has entered the phase-3 clinical trial in the United Arab Emirates, according to Sinopharm's China National Biotec Group (CNBG) on Tuesday, 23 June.

This is the first company in China to conduct an overseas clinical trial of the COVID-19 vaccine, state broadcaster CGTN reported.

The vaccine, developed by the Wuhan Institute of Biological Products under CNBG affiliated to Sinopharm, has shown promising results in terms of both safety and efficacy in phase-1 and phase-2 clinical trials.

The CNBG is actively promoting overseas cooperation in the phase-3 clinical trial of the vaccine.

This is primarily because there are currently not enough COVID-19 patients in China required for a phase-3 clinical trial, according to experts.

The company has already secured the intention of the cooperation of several firms and research institutions from different countries.

(The Quint is now available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

(This story was auto-published from a syndicated feed. No part of the story has been edited by The Quint.)

Never Miss Out

Stay tuned with our weekly recap of what’s hot & cool by The Quint.

Join over 120,000 subscribers!